摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

phenyl 3-(5-methyltetrazol-1-yl)phenylcarbamate | 865540-80-3

中文名称
——
中文别名
——
英文名称
phenyl 3-(5-methyltetrazol-1-yl)phenylcarbamate
英文别名
phenyl N-[3-(5-methyltetrazol-1-yl)phenyl]carbamate
phenyl 3-(5-methyltetrazol-1-yl)phenylcarbamate化学式
CAS
865540-80-3
化学式
C15H13N5O2
mdl
——
分子量
295.301
InChiKey
CMGNYOISKAALAN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.33±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    81.9
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    phenyl 3-(5-methyltetrazol-1-yl)phenylcarbamate(1R,2S)-2-(((S)-3-(4-fluorobenzyl)piperidin-1-yl)methyl)cyclohexylamine乙腈 为溶剂, 生成 1-{(1R,2S)-2-[(S)-3-(4-Fluoro-benzyl)-piperidin-1-ylmethyl]-cyclohexyl}-3-[3-(5-methyl-tetrazol-1-yl)-phenyl]-urea
    参考文献:
    名称:
    Discovery of CC Chemokine Receptor-3 (CCR3) Antagonists with Picomolar Potency
    摘要:
    Starting with our previously described(20) class of CC chemokine receptor-3 (CCR3) antagonist, we improved the potency by replacing the phenyl linker of 1 with a cyclohexyl linker and by replacing the 4-benzylpiperidine with a 3-benzylpiperidine. The resulting compound, 32, is a potent and selective antagonist of CCR3. SAR studies showed that the 3-acetylphenyl urea of 32 could be replaced with heterocyclic ureas or heterocyclic-substituted phenyl ureas and still maintain the potency (inhibition of eotaxin-induced chemotaxis) of this class of compounds in the low-picomolar range (IC50 = 10-60 pM), representing some of the most potent CCR3 antagonists reported to date. The potency of 32 for mouse CCR3 (chemotaxis IC50 = 41 nM) and its oral bioavailability in mice (20% F) were adequate to assess the efficacy in animal models of allergic airway inflammation. Oral administration of 32 reduced eosinophil recruitment into the lungs in a dose-dependent manner in these animal models. On the basis of its overall potency, selectivity, efficacy, and safety profile, the benzenesulfonate salt of 32, designated DPC168, entered phase 1 clinical trials.
    DOI:
    10.1021/jm049530m
  • 作为产物:
    描述:
    间硝基苯甲酰氯 在 palladium on activated charcoal 2,6-二甲基吡啶 、 sodium azide 、 氢气trifluoromethanesulfonic acid anhydride 作用下, 以 四氢呋喃甲醇二氯甲烷乙酸乙酯乙腈 为溶剂, 反应 2.0h, 生成 phenyl 3-(5-methyltetrazol-1-yl)phenylcarbamate
    参考文献:
    名称:
    Discovery of CC Chemokine Receptor-3 (CCR3) Antagonists with Picomolar Potency
    摘要:
    Starting with our previously described(20) class of CC chemokine receptor-3 (CCR3) antagonist, we improved the potency by replacing the phenyl linker of 1 with a cyclohexyl linker and by replacing the 4-benzylpiperidine with a 3-benzylpiperidine. The resulting compound, 32, is a potent and selective antagonist of CCR3. SAR studies showed that the 3-acetylphenyl urea of 32 could be replaced with heterocyclic ureas or heterocyclic-substituted phenyl ureas and still maintain the potency (inhibition of eotaxin-induced chemotaxis) of this class of compounds in the low-picomolar range (IC50 = 10-60 pM), representing some of the most potent CCR3 antagonists reported to date. The potency of 32 for mouse CCR3 (chemotaxis IC50 = 41 nM) and its oral bioavailability in mice (20% F) were adequate to assess the efficacy in animal models of allergic airway inflammation. Oral administration of 32 reduced eosinophil recruitment into the lungs in a dose-dependent manner in these animal models. On the basis of its overall potency, selectivity, efficacy, and safety profile, the benzenesulfonate salt of 32, designated DPC168, entered phase 1 clinical trials.
    DOI:
    10.1021/jm049530m
点击查看最新优质反应信息

文献信息

  • Modulators of Chemokine Receptor Activity
    申请人:Weigand Klaus
    公开号:US20080306067A1
    公开(公告)日:2008-12-11
    A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.
    公式为(I)的化合物,其取代基如上所述,在治疗由CCR3作用介导的疾病中有用,特别是炎症或阻塞性气道疾病。
  • WO2007/48771
    申请人:——
    公开号:——
    公开(公告)日:——
  • ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    申请人:Novartis AG
    公开号:EP1943235A1
    公开(公告)日:2008-07-16
  • [EN] ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] DÉRIVÉS ARYLURÉE EN TANT QUE MODULATEURS D'ACTIVITÉ DE RÉCEPTEUR CHIMIOKINE
    申请人:NOVARTIS AG
    公开号:WO2007048771A1
    公开(公告)日:2007-05-03
    [EN] A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.
    [FR] L'invention concerne un composé de formule (I), dont les substituants sont comme décrits ci-dessus, utile dans le traitement d'une maladie par l'action indirecte de CCR3, en particulier des maladies inflammatoires ou obstructives des voies respiratoires.
查看更多